Skip to content

Prostatic Cancer Versus Androgen Deficiency

Localised Cancer of Prostate and Androgen Deficiency.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02235142
Acronym
AndroCan
Enrollment
1614
Registered
2014-09-09
Start date
2013-06-03
Completion date
2021-12-22
Last updated
2022-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of Prostate

Brief summary

Open study to make a comparison between hypogonadism and euogonadism patients regarding the severity of prostate cancer. The purpose of this study is to determine the importance of the relationship between the hormonal status and the type of the tumor at the time of surgical intervention as well as follow up of the patients.

Interventions

OTHERBlood sample

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male patients over than 18 years of age, with localized, stage I or II prostate cancer, not receiving local treatment (radiation, phototherapy, thermotherapy,…) or hormonal therapy, showing indication of radical prostatectomy.

Exclusion criteria

* Absence of radical prostatectomy indication * Patient received local or hormonal therapy prior to surgery * Patients already enrolled in other clinical study incompatible with the study * Patients on a treatment which can affect hormonal level (Prednisone, Ketoconazole, Abiraterone, Finasteride, Dutasteride)

Design outcomes

Primary

MeasureTime frame
Testosteron Serum levelThe day prior to surgery
Gleason score5 years

Countries

France, Guadeloupe, Martinique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026